1. 107PPhase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): Phase Ib results. (25th November 2018) Authors: Kagawa, Y; Satake, H; Kato, T; Oba, K; Yasui, H; Nakamura, M; Watanabe, T; Hirata, K; Muro, K; Komatsu, Y; Yoshino, T; Yamazaki, K; Mishima, H; Kotaka, M; Tsuji, A; Kakeji, Y; Oki, E; Nagata, N; Junichi, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 29TiPA translational study to discover novel host-related immune-biomarkers for nivolumab (Nivo) in advanced gastric cancer (GC): JACCRO GC-08 (DELIVER trial). (17th December 2018) Authors: Sunakawa, Y; Muro, K; Nakajima, T E; Kawakami, H; Inoue, E; Matoba, R; Sato, Y; Ichikawa, W; Fujii, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 389PRisk factors of nivolumab-induced pneumonitis in patients with solid tumors. (25th November 2018) Authors: Yamaguchi, T; Hasegawa, T; Hanai, N; Inaba, Y; Muro, K; Hida, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 454PDInfluence of treatment with prior bevacizumab: A combined analysis of individual patient data from ASPECCT and WJOG6510G trial which compared panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer. (23rd October 2018) Authors: Taniguchi, H; Yamanaka, T; Sakai, D; Yamazaki, K; Muro, K; Peeters, M; Price, T J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 488PHistopathologic evaluation of patients with liver-limited metastatic colorectal cancer receiving mFOLFOX6 plus bevacizumab or mFOLFOX6 plus cetuximab: The ATOM trial. (23rd October 2018) Authors: Emi, Y; Yamanaka, T; Muro, K; Uetake, H; Oki, E; Takahashi, T; Katayose, Y; Yoshida, K; Sakamoto, M; Aishima, S; Ishida, K; Imura, J; Unno, M; Hyodo, I; Tomita, N; Sugihara, K; Maehara, Y Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 606TiPRandomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G. (23rd October 2018) Authors: Kito, Y; Yamada, T; Matsumoto, T; Yasui, H; Murata, K; Makiyama, A; Hara, H; Baba, E; Nishio, K; Yoshimura, K; Hironaka, S; Muro, K; Yamazaki, K Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 617PDA phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data. (23rd October 2018) Authors: Satoh, T; Chen, L-T; Kang, Y-K; Chao, Y; Kato, K; Chung, H C; Chen, J-S; Muro, K; Kang, W K; Yoshikawa, T; Oh, S C; Tamura, T; Lee, K-W; Boku, N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 659PAvelumab (anti–PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): Updated results from the phase Ib JAVELIN solid tumour JPN trial. (23rd October 2018) Authors: Doi, T; Iwasa, S; Muro, K; Satoh, T; Hironaka, S; Esaki, T; Nishina, T; Hara, H; Machida, N; Komatsu, Y; Shimada, Y; Otsu, S; Shimizu, S; Chand, V; Watanabe, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 661PUpdated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with pretreated recurrent or refractory gastric cancer. (23rd October 2018) Authors: Bang, Y-J; Doi, T; Kondo, S; Chung, H C; Muro, K; Dussault, I; Helwig, C; Osada, M; Kang, Y-K Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 681PImpact of adding ramucirumab to paclitaxel in patients with advanced gastric cancer according to the level of ascites: A multicenter retrospective study. (23rd October 2018) Authors: Masuishi, T; Kadowaki, S; Hirano, H; Kawai, S; Yamada, T; Moriwaki, T; Machida, N; Boku, N; Muro, K Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗